Comparing Cidara Therapeutics (CDTX) and Nantkwest (NK)

Cidara Therapeutics (NASDAQ:CDTX) and Nantkwest (NASDAQ:NK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.

Insider and Institutional Ownership

65.2% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 13.6% of Nantkwest shares are owned by institutional investors. 15.2% of Cidara Therapeutics shares are owned by insiders. Comparatively, 72.3% of Nantkwest shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Cidara Therapeutics and Nantkwest’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cidara Therapeutics N/A N/A -$55.72 million ($3.18) -1.05
Nantkwest $50,000.00 2,440.28 -$96.42 million ($1.20) -1.28

Cidara Therapeutics has higher earnings, but lower revenue than Nantkwest. Nantkwest is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cidara Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Nantkwest has a beta of 3.09, meaning that its stock price is 209% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Cidara Therapeutics and Nantkwest, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cidara Therapeutics 0 0 4 0 3.00
Nantkwest 0 3 0 0 2.00

Cidara Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 270.37%. Nantkwest has a consensus target price of $3.25, indicating a potential upside of 111.04%. Given Cidara Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Cidara Therapeutics is more favorable than Nantkwest.

Profitability

This table compares Cidara Therapeutics and Nantkwest’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cidara Therapeutics N/A -91.51% -68.87%
Nantkwest -198,790.38% -54.20% -46.28%

Summary

Cidara Therapeutics beats Nantkwest on 7 of the 13 factors compared between the two stocks.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Nantkwest Company Profile

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply